Resistance of hepatitis C virus to inhibitors: Complexity and clinical implications

Viruses

Volumn 7, Issue 11, 2015, Pages 5746-5766

  Perales, Celia ^a,b,c   Quer, Josep ^a,c,d   Gregori, Josep ^a,c,e   Esteban, Juan Ignacio ^a,c,d   Domingo, Esteban ^b,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b CENTRO DE BIOLOGÍA MOLECULAR SEVERO OCHOA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e Roche Diagnostics SL   (Spain)

Author keywords

Antiviral treatment; Hepatitis C virus; Viral quasi species; Viral resistance

Indexed keywords

ALISPORIVIR; ANTIVIRUS AGENT; BOCEPREVIR; CYCLOPHILIN A; DACLATASVIR; DANOPREVIR; DASABUVIR; GUANOSINE TRIPHOSPHATE; INTERFERON; LEDIPASVIR; OMBITASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PARITAPREVIR; RIBAVIRIN; RITONAVIR; RNA DIRECTED RNA POLYMERASE; SIMEPREVIR; TELAPREVIR; VANIPREVIR; VIRUS ENZYME;

AMINO ACID SUBSTITUTION; CLINICAL TRIAL (TOPIC); DRUG TARGETING; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; NONHUMAN; REVIEW; RNA CAPPING; TREATMENT FAILURE; VIRUS GENOME; VIRUS INHIBITION; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS STRAIN; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENETIC VARIATION; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; HEPACIVIRUS; PHENOTYPE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENETIC VARIATION; GENOTYPE; HEPACIVIRUS; HUMANS; PHENOTYPE;

EID: 84946925215     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7112902     Document Type: Review

References (159)

1. Mas, A.; Lopez-Galindez, C.; Cacho, I.; Gomez, J.; Martinez, M.A. Unfinished stories on viral quasispecies and Darwinian views of evolution. J. Mol. Biol. 2010, 397, 865-877. [CrossRef] [PubMed]
2. Ojosnegros, S.; Perales, C.; Mas, A.; Domingo, E. Quasispecies as a matter of fact: Viruses and beyond. Virus Res. 2011, 162, 203-215. [CrossRef] [PubMed]
3. Domingo, E. Virus as Populations ; Academic Press: Waltham, MA, USA; Elsevier: Amsterdam, The Netherlands, 2015.
4. Domingo, E.; Schuster, P. What is a quasispecies? Historical origins and current scope. Curr. Top. Microbiol. Immunol. 2015. in press.
5. Bartolini, B.; Lionetti, R.; Giombini, E.; Sias, C.; Taibi, C.; Montalbano, M.; Gianpiero, D.; McPhee, F.; Hughes, E.A.; Zhou, N.; et al. Dynamics of HCV genotype 4 resistance-associated variants during virologic escape with pIFN/RBV + daclatasvir: A case study using ultra deep pyrosequencing. J. Clin. Virol. 2015, 66, 38-43. [CrossRef] [PubMed]
6. Ji, H.; Kozak, R.A.; Biondi, M.J.; Pilon, R.; Vallee, D.; Liang, B.B.; La, D.; Kim, J.; van Domselaar, G.; Leonard, L.; et al. Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations. Virology 2015, 477, 1-9. [CrossRef] [PubMed]
7. Ogishi, M.; Yotsuyanagi, H.; Tsutsumi, T.; Gatanaga, H.; Ode, H.; Sugiura, W.; Moriya, K.; Oka, S.; Kimura, S.; Koike, K. Deconvoluting the composition of low-frequency hepatitis C viral quasispecies: Comparison of genotypes and NS3 resistance-associated variants between HCV/HIV coinfected hemophiliacs and HCV monoinfected patients in Japan. PLoS ONE 2015, 10, e0119145. [CrossRef] [PubMed]
8. Hirotsu, Y.; Kanda, T.; Matsumura, H.; Moriyama, M.; Yokosuka, O.; Omata, M. HCV NS5A resistance-associated variants in a group of real-world Japanese patients chronically infected with HCV genotype 1b. Hepatol. Int. 2015, 9, 424-430. [CrossRef] [PubMed]
9. Thys, K.; Verhasselt, P.; Reumers, J.; Verbist, B.M.; Maes, B.; Aerssens, J. Performance assessment of the Illumina massively parallel sequencing platform for deep sequencing analysis of viral minority variants. J. Virol. Methods 2015, 221, 29-38. [CrossRef] [PubMed]
10. Simen, B.B.; Braverman, M.S.; Abbate, I.; Aerssens, J.; Bidet, Y.; Bouchez, O.; Gabriel, C.; Izopet, J.; Kessler, H.H.; Stelzl, E.; et al. An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. J. Virol. Methods 2014, 204, 31-37. [CrossRef] [PubMed]
11. Liu, L.; Li, Y.; Li, S.; Hu, N.; He, Y.; Pong, R.; Lin, D.; Lu, L.; Law, M. Comparison of next-generation sequencing systems. J. Biomed. Biotechnol. 2012, 2012. [CrossRef] [PubMed]
12. Arias, A.; Lázaro, E.; Escarmís, C.; Domingo, E. Molecular intermediates of fitness gain of an RNA virus: Characterization of a mutant spectrum by biological and molecular cloning. J. Gen. Virol. 2001, 82, 1049-1060. [CrossRef] [PubMed]
13. Domingo, E.; Sheldon, J.; Perales, C. Viral quasispecies evolution. Microbiol. Mol. Biol. Rev. 2012, 76, 159-216. [CrossRef] [PubMed]
14. Palmer, S.; Kearney, M.; Maldarelli, F.; Halvas, E.K.; Bixby, C.J.; Bazmi, H.; Rock, D.; Falloon, J.; Davey, R.T., Jr.; Dewar, R.L.; et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 2005, 43, 406-413. [CrossRef] [PubMed]
15. Bao, R.; Huang, L.; Andrade, J.; Tan, W.; Kibbe, W.A.; Jiang, H.; Feng, G. Review of current methods, applications, and data management for the bioinformatics analysis of whole exome sequencing. Cancer Inform. 2014, 13, 67-82. [PubMed]
16. Pabinger, S.; Dander, A.; Fischer, M.; Snajder, R.; Sperk, M.; Efremova, M.; Krabichler, B.; Speicher, M.R.; Zschocke, J.; Trajanoski, Z. A survey of tools for variant analysis of next-generation genome sequencing data. Brief. Bioinform. 2014, 15, 256-278. [CrossRef] [PubMed]
17. El-Metwally, S.; Hamza, T.; Zakaria, M.; Helmy, M. Next-generation sequence assembly: Four stages of data processing and computational challenges. PLoS Comput. Biol. 2013, 9, e1003345. [CrossRef] [PubMed]
18. Magi, A.; Benelli, M.; Gozzini, A.; Girolami, F.; Torricelli, F.; Brandi, M.L. Bioinformatics for next generation sequencing data. Genes 2010, 1, 294-307. [CrossRef] [PubMed]
19. Gregori, J.; Esteban, J.I.; Cubero, M.; Garcia-Cehic, D.; Perales, C.; Casillas, R.; Alvarez-Tejado, M.; Rodriguez-Frias, F.; Guardia, J.; Domingo, E.; et al. Ultra-Deep Pyrosequencing (UDPS) Data Treatment to Study Amplicon HCV Minor Variants. PLoS ONE 2013, 8, e83361. [CrossRef] [PubMed]
20. Ramirez, C.; Gregori, J.; Buti, M.; Tabernero, D.; Camos, S.; Casillas, R.; Quer, J.; Esteban, R.; Homs, M.; Rodriguez-Frias, F. A comparative study of ultra-deep pyrosequencing and cloning to quantitatively analyze the viral quasispecies using hepatitis B virus infection as a model. Antivir. Res. 2013, 98, 273-283. [CrossRef] [PubMed]
21. Li, M.; Stoneking, M. A new approach for detecting low-level mutations in next-generation sequence data. Genome Biol. 2012, 13. [CrossRef] [PubMed]
22. Nakamura, K.; Oshima, T.; Morimoto, T.; Ikeda, S.; Yoshikawa, H.; Shiwa, Y.; Ishikawa, S.; Linak, M.C.; Hirai, A.; Takahashi, H.; et al. Sequence-specific error profile of Illumina sequencers. Nucl. Acids Res. 2011, 39. [CrossRef] [PubMed]
23. Nguyen, P.; Ma, J.; Pei, D.; Obert, C.; Cheng, C.; Geiger, T.L. Identification of errors introduced during high throughput sequencing of the T cell receptor repertoire. BMC Genom. 2011, 12. [CrossRef] [PubMed]
24. De Leeneer, K.; de Schrijver, J.; Clement, L.; Baetens, M.; Lefever, S.; de Keulenaer, S.; van Criekinge, W.; Deforce, D.; van Nieuwerburgh, F.; Bekaert, S.; et al. Practical tools to implement massive parallel pyrosequencing of PCR products in next generation molecular diagnostics. PLoS ONE 2011, 6, e25531. [CrossRef] [PubMed]
25. Giallonardo, F.D.; Topfer, A.; Rey, M.; Prabhakaran, S.; Duport, Y.; Leemann, C.; Schmutz, S.; Campbell, N.K.; Joos, B.; Lecca, M.R.; et al. Full-length haplotype reconstruction to infer the structure of heterogeneous virus populations. Nucl. Acids Res. 2014, 42. [CrossRef] [PubMed]
26. Acevedo, A.; Brodsky, L.; Andino, R. Mutational and fitness landscapes of an RNA virus revealed through population sequencing. Nature 2014, 505, 686-690. [CrossRef] [PubMed]
27. Eigen, M. Self-organization of matter and the evolution of biological macromolecules. Naturwissenschaften 1971, 58, 465-523. [CrossRef] [PubMed]
28. Eigen, M.; Schuster, P. The Hypercycle. A Principle of Natural Self-Organization ; Springer: Berlin, Germany, 1979.
29. Page, K.M.; Nowak, M.A. Unifying evolutionary dynamics. J. Theor. Biol. 2002, 219, 93-98. [CrossRef]
30. Ferrer-Orta, C.; Agudo, R.; Domingo, E.; Verdaguer, N. Structural insights into replication initiation and elongation processes by the FMDV RNA-dependent RNA polymerase. Curr. Opin. Struct. Biol. 2009, 19, 752-758. [CrossRef] [PubMed]
31. Campagnola, G.; McDonald, S.; Beaucourt, S.; Vignuzzi, M.; Peersen, O.B. Structure-function relationships underlying the replication fidelity of viral RNA-dependent RNA polymerases. J. Virol. 2015, 89, 275-286. [CrossRef] [PubMed]
32. Friedberg, E.C.; Walker, G.C.; Siede, W.; Wood, R.D.; Schultz, R.A.; Ellenberger, T. DNA Repair and Mutagenesis ; American Society for Microbiology: Washington, DC, USA, 2006.
33. Eigen, M.; Biebricher, C.K. Sequence space and quasispecies distribution. In RNA Genetics ; Domingo, E., Ahlquist, P., Holland, J.J., Eds.; CRC Press: Boca Raton, FL, USA, 1988; Volume 3, pp. 211-245.
34. Lauring, A.S.; Andino, R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010, 6, e1001005. [CrossRef] [PubMed]
35. Schuster, P. Quasispecies on fitness landscapes. Curr. Top. Microbiol. Immunol. 2015. in press.
36. Bordería, A.V.; Rozen-Gagnon, K.; Vignuzzi, M. Fidelity variants and RNA quasispecies. Curr. Top. Microbiol. Immunol. 2015, in press.
37. Ke, R.; Loverdo, C.; Qi, H.; Sun, R.; Lloyd-Smith, J.O. Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection. PLoS Comput. Biol. 2015, 11, e1004040. [CrossRef] [PubMed]
38. Eggers, H.J.; Tamm, I. Coxsackie A9 virus: Mutation from drug dependence to drug independence. Science 1965, 148, 97-98. [CrossRef] [PubMed]
39. Melnick, J.L.; Crowther, D.; Barrera-Oro, J. Rapid development of drug-resistant mutants of poliovirus. Science 1961, 134. [CrossRef]
40. Domingo, E. RNA virus evolution and the control of viral disease. Prog. Drug Res. 1989, 33, 93-133. [PubMed]
41. Richman, D.D., Ed.; Antiviral Drug Resistance ; John Wiley and Sons Inc.: New York, NY, USA, 1996.
42. Lam, N.P.; Neumann, A.U.; Gretch, D.R.; Wiley, T.E.; Perelson, A.S.; Layden, T.J. Dose-dependent acute clearance of hepatitis C genotype 1 virus with interferon α. Hepatology 1997, 26, 226-231. [CrossRef] [PubMed]
43. Zeuzem, S.; Schmidt, J.M.; Lee, J.H.; Ruster, B.; Roth, W.K. Effect of interferon α on the dynamics of hepatitis C virus turnover in vivo. Hepatology 1996, 23, 366-371. [CrossRef] [PubMed]
44. Perales, C.; Beach, N.M.; Gallego, I.; Soria, M.E.; Quer, J.; Esteban, J.I.; Rice, C.; Domingo, E.; Sheldon, J. Response of hepatitis C virus to long-term passage in the presence of α interferon: Multiple mutations and a common phenotype. J. Virol. 2013, 87, 7593-7607. [CrossRef] [PubMed]
45. Davis, G.L.; Esteban-Mur, R.; Rustgi, V.; Hoefs, J.; Gordon, S.C.; Trepo, C.; Shiffman, M.L.; Zeuzem, S.; Craxi, A.; Ling, M.H.; et al. Interferon α-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998, 339, 1493-1499. [CrossRef] [PubMed]
46. Poynard, T.; Marcellin, P.; Lee, S.S.; Niederau, C.; Minuk, G.S.; Ideo, G.; Bain, V.; Heathcote, J.; Zeuzem, S.; Trepo, C.; et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998, 352, 1426-1432. [CrossRef]
47. Manns, M.P.; McHutchison, J.G.; Gordon, S.C.; Rustgi, V.K.; Shiffman, M.; Reindollar, R.; Goodman, Z.D.; Koury, K.; Ling, M.; Albrecht, J.K. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 2001, 358, 958-965. [CrossRef]
48. Lindsay, K.L.; Trepo, C.; Heintges, T.; Shiffman, M.L.; Gordon, S.C.; Hoefs, J.C.; Schiff, E.R.; Goodman, Z.D.; Laughlin, M.; Yao, R.; et al. A randomized, double-blind trial comparing pegylated interferon α-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology 2001, 34, 395-403. [CrossRef] [PubMed]
49. Hadziyannis, S.J.; Sette, H., Jr.; Morgan, T.R.; Balan, V.; Diago, M.; Marcellin, P.; Ramadori, G.; Bodenheimer, H., Jr.; Bernstein, D.; Rizzetto, M.; et al. Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann. Intern. Med. 2004, 140, 346-355. [CrossRef] [PubMed]
50. Zeuzem, S.; Hultcrantz, R.; Bourliere, M.; Goeser, T.; Marcellin, P.; Sanchez-Tapias, J.; Sarrazin, C.; Harvey, J.; Brass, C.; Albrecht, J. Peginterferon α-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J. Hepatol. 2004, 40, 993-999. [CrossRef] [PubMed]
51. Nguyen, M.H.; Keeffe, E.B. Prevalence and treatment of hepatitis C virus genotypes 4, 5, and 6. Clin. Gastroenterol. Hepatol. 2005, 3, S97-S101. [CrossRef]
52. Antaki, N.; Hermes, A.; Hadad, M.; Ftayeh, M.; Antaki, F.; Abdo, N.; Kebbewar, K. Efficacy of interferon plus ribavirin in the treatment of hepatitis C virus genotype 5. J. Viral Hepat. 2008, 15, 383-386. [CrossRef] [PubMed]
53. Kamal, S.M.; el Tawil, A.A.; Nakano, T.; He, Q.; Rasenack, J.; Hakam, S.A.; Saleh, W.A.; Ismail, A.; Aziz, A.A.; Madwar, M.A. Peginterferon α-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response. Gut 2005, 54, 858-866. [CrossRef] [PubMed]
54. Sostegni, R.; Ghisetti, V.; Pittaluga, F.; Marchiaro, G.; Rocca, G.; Borghesio, E.; Rizzetto, M.; Saracco, G. Sequential versus concomitant administration of ribavirin and interferon α-n3 in patients with chronic hepatitis C not responding to interferon alone: Results of a randomized, controlled trial. Hepatology 1998, 28, 341-346. [CrossRef] [PubMed]
55. Asahina, Y.; Izumi, N.; Enomoto, N.; Uchihara, M.; Kurosaki, M.; Onuki, Y.; Nishimura, Y.; Ueda, K.; Tsuchiya, K.; Nakanishi, H.; et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J. Hepatol. 2005, 43, 623-629. [CrossRef] [PubMed]
56. Cuevas, J.M.; Gonzalez-Candelas, F.; Moya, A.; Sanjuan, R. Effect of ribavirin on the mutation rate and spectrum of hepatitis C virus in vivo. J. Virol. 2009, 83, 5760-5764. [CrossRef] [PubMed]
57. Dietz, J.; Schelhorn, S.E.; Fitting, D.; Mihm, U.; Susser, S.; Welker, M.W.; Fuller, C.; Daumer, M.; Teuber, G.; Wedemeyer, H.; et al. Deep sequencing reveals mutagenic effects of ribavirin during monotherapy of hepatitis C virus genotype 1-infected patients. J. Virol. 2013, 87, 6172-6181. [CrossRef] [PubMed]
58. Dixit, N.M.; Layden-Almer, J.E.; Layden, T.J.; Perelson, A.S. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432, 922-924. [CrossRef] [PubMed]
59. Lutchman, G.; Danehower, S.; Song, B.C.; Liang, T.J.; Hoofnagle, J.H.; Thomson, M.; Ghany, M.G. Mutation rate of the hepatitis C virus NS5B in patients undergoing treatment with ribavirin monotherapy. Gastroenterology 2007, 132, 1757-1766. [CrossRef] [PubMed]
60. Ortega-Prieto, A.M.; Sheldon, J.; Grande-Perez, A.; Tejero, H.; Gregori, J.; Quer, J.; Esteban, J.I.; Domingo, E.; Perales, C. Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis. PLoS ONE 2013, 8, e71039. [CrossRef] [PubMed]
61. Young, K.C.; Lindsay, K.L.; Lee, K.J.; Liu, W.C.; He, J.W.; Milstein, S.L.; Lai, M.M. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 2003, 38, 869-878. [CrossRef] [PubMed]
62. Ibarra, K.D.; Pfeiffer, J.K. Reduced ribavirin antiviral efficacy via nucleoside transporter-mediated drug resistance. J. Virol. 2009, 83, 4538-4547. [CrossRef] [PubMed]
63. Pfeiffer, J.K.; Kirkegaard, K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. J. Virol. 2005, 79, 2346-2355. [CrossRef] [PubMed]
64. Hmwe, S.S.; Aizaki, H.; Date, T.; Murakami, K.; Ishii, K.; Miyamura, T.; Koike, K.; Wakita, T.; Suzuki, T. Identification of hepatitis C virus genotype 2a replicon variants with reduced susceptibility to ribavirin. Antivir. Res. 2010, 85, 520-524. [CrossRef] [PubMed]
65. Feigelstock, D.A.; Mihalik, K.B.; Feinstone, S.M. Selection of hepatitis C virus resistant to ribavirin. Virol. J. 2011, 8. [CrossRef] [PubMed]
66. Barth, H. Hepatitis C virus: Is it time to say goodbye yet? Perspectives and challenges for the next decade. World J. Hepatol. 2015, 7, 725-737. [CrossRef] [PubMed]
67. Horner, S.M.; Naggie, S. Successes and Challenges on the Road to Cure Hepatitis C. PLoS Pathog. 2015, 11, e1004854. [CrossRef] [PubMed]
68. Pawlotsky, J.M. Hepatitis C treatment: The data flood goes on-an update from the liver meeting 2014. Gastroenterology 2015, 148, 468-479. [CrossRef] [PubMed]
69. Conteduca, V.; Sansonno, D.; Russi, S.; Pavone, F.; Dammacco, F. Therapy of chronic hepatitis C virus infection in the era of direct-acting and host-targeting antiviral agents. J. Infect. 2014, 68, 1-20. [CrossRef] [PubMed]
70. DeLemos, A.S.; Chung, R.T. Hepatitis C treatment: An incipient therapeutic revolution. Trends Mol. Med. 2014, 20, 315-321. [CrossRef] [PubMed]
71. Feld, J.J. The beginning of the end: What is the future of interferon therapy for chronic hepatitis C? Antivir. Res. 2014, 105, 32-38. [CrossRef] [PubMed]
72. Hayes, C.N.; Chayama, K. Emerging treatments for chronic hepatitis C. J. Formos. Med. Assoc. 2015, 114, 204-215. [CrossRef] [PubMed]
73. Solund, C.; Krarup, H.; Ramirez, S.; Thielsen, P.; Roge, B.T.; Lunding, S.; Barfod, T.S.; Madsen, L.G.; Tarp, B.; Christensen, P.B.; et al. Nationwide experience of treatment with protease inhibitors in chronic hepatitis C patients in denmark: Identification of viral resistance mutations. PLoS ONE 2014, 9, e113034. [CrossRef] [PubMed]
74. Vermehren, J.; Sarrazin, C. The role of resistance in HCV treatment. Best Pract. Res. Clin. Gastroenterol. 2012, 26, 487-503. [CrossRef] [PubMed]
75. Lontok, E.; Harrington, P.; Howe, A.; Kieffer, T.; Lennerstrand, J.; Lenz, O.; McPhee, F.; Mo, H.; Parkin, N.; Pilot-Matias, T.; et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 2015, 62, 1623-32. [CrossRef] [PubMed]
76. Lange, C.M.; Zeuzem, S. Perspectives and challenges of interferon-free therapy for chronic hepatitis C. J. Hepatol. 2013, 58, 583-592. [CrossRef] [PubMed]
77. Thompson, A.J.; Locarnini, S.A.; Beard, M.R. Resistance to anti-HCV protease inhibitors. Curr. Opin. Virol. 2011, 1, 599-606. [CrossRef] [PubMed]
78. Sarrazin, C.; Zeuzem, S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138, 447-462. [CrossRef] [PubMed]
79. Wyles, D.L. Antiviral resistance and the future landscape of hepatitis C virus infection therapy. J. Infect. Dis. 2013, 207, S33-S39. [CrossRef] [PubMed]
80. Gao, M. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Curr. Opin. Virol. 2013, 3, 514-520. [CrossRef] [PubMed]
81. Halfon, P.; Sarrazin, C. Future treatment of chronic hepatitis C with direct acting antivirals: Is resistance important? Liver Int. 2012, 32, 79-87. [CrossRef] [PubMed]
82. Nakamoto, S.; Kanda, T.; Wu, S.; Shirasawa, H.; Yokosuka, O. Hepatitis C virus NS5A inhibitors and drug resistance mutations. World J. Gastroenterol. 2014, 20, 2902-2912. [CrossRef] [PubMed]
83. Nettles, R.E.; Gao, M.; Bifano, M.; Chung, E.; Persson, A.; Marbury, T.C.; Goldwater, R.; DeMicco, M.P.; Rodriguez-Torres, M.; Vutikullird, A.; et al. Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1. Hepatology 2011, 54, 1956-1965. [CrossRef] [PubMed]
84. Lam, A.M.; Espiritu, C.; Bansal, S.; Micolochick Steuer, H.M.; Niu, C.; Zennou, V.; Keilman, M.; Zhu, Y.; Lan, S.; Otto, M.J.; et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrob. Agents Chemother. 2012, 56, 3359-3368. [CrossRef] [PubMed]
85. Donaldson, E.F.; Harrington, P.R.; O'Rear, J.J.; Naeger, L.K. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology 2015, 61, 56-65. [CrossRef] [PubMed]
86. Tong, X.; le Pogam, S.; Li, L.; Haines, K.; Piso, K.; Baronas, V.; Yan, J.M.; So, S.S.; Klumpp, K.; Najera, I. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J. Infect. Dis. 2014, 209, 668-675. [CrossRef] [PubMed]
87. Childs-Kean, L.M.; Hand, E.O. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection. Clin. Ther. 2015, 37, 243-267. [CrossRef] [PubMed]
88. Gane, E.J.; Stedman, C.A.; Hyland, R.H.; Ding, X.; Svarovskaia, E.; Symonds, W.T.; Hindes, R.G.; Berrey, M.M. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N. Engl. J. Med. 2013, 368, 34-44. [CrossRef] [PubMed]
89. Hedskog, C.; Dvory-Sobol, H.; Gontcharova, V.; Martin, R.; Ouyang, W.; Han, B.; Gane, E.J.; Brainard, D.; Hyland, R.H.; Miller, M.D.; et al. Evolution of the HCV viral population from a patient with S282T detected at relapse after sofosbuvir monotherapy. J. Viral Hepat. 2015, 22, 871-881. [CrossRef] [PubMed]
90. Svarovskaia, E.S.; Dvory-Sobol, H.; Parkin, N.; Hebner, C.; Gontcharova, V.; Martin, R.; Ouyang, W.; Han, B.; Xu, S.; Ku, K.; et al. Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin. Infect. Dis. 2014, 59, 1666-1674. [CrossRef] [PubMed]
91. Osinusi, A.; Meissner, E.G.; Lee, Y.J.; Bon, D.; Heytens, L.; Nelson, A.; Sneller, M.; Kohli, A.; Barrett, L.; Proschan, M.; et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: A randomized clinical trial. JAMA 2013, 310, 804-811. [CrossRef] [PubMed]
92. Lawitz, E.; Poordad, F.F.; Pang, P.S.; Hyland, R.H.; Ding, X.; Mo, H.; Symonds, W.T.; McHutchison, J.G.; Membreno, F.E. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): An open-label, randomised, phase 2 trial. Lancet 2014, 383, 515-523. [CrossRef]
93. Maimone, S.; Tripodi, G.; Musolino, C.; Cacciola, I.; Pollicino, T.; Raimondo, G. Lack of the NS5B S282T mutation in HCV isolates from liver tissue of treatment-naive patients with HCV genotype-1b infection. Antivir. Ther. 2015, 20, 245-247. [CrossRef] [PubMed]
94. Smith, D.B.; Bukh, J.; Kuiken, C.; Muerhoff, A.S.; Rice, C.M.; Stapleton, J.T.; Simmonds, P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource. Hepatology 2014, 59, 318-327. [CrossRef] [PubMed]
95. McCown, M.F.; Rajyaguru, S.; Kular, S.; Cammack, N.; Najera, I. GT-1a or GT-1b subtype-specific resistance profiles for hepatitis C virus inhibitors telaprevir and HCV-796. Antimicrob. Agents Chemother. 2009, 53, 2129-2132. [CrossRef] [PubMed]
96. Quer, J.; Gregori, J.; Rodriguez-Frias, F.; Buti, M.; Madejon, A.; Perez-del-Pulgar, S.; Garcia-Cehic, D.; Casillas, R.; Blasi, M.; Homs, M.; et al. High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods. J. Clin. Microbiol. 2015, 53, 219-226. [CrossRef] [PubMed]
97. Los Alamos database. Available online: https://hcv.lanl.gov/content/sequence/HCV/ToolsOutline.html (accessed on 19 February 2015).
98. Perales, C.; Beach, N.M.; Sheldon, J.; Domingo, E. Molecular basis of interferon resistance in hepatitis C virus. Curr. Opin. Virol. 2014, 8C, 38-44. [CrossRef] [PubMed]
99. Geller, R.; Vignuzzi, M.; Andino, R.; Frydman, J. Evolutionary constraints on chaperone-mediated folding provide an antiviral approach refractory to development of drug resistance. Genes Dev. 2007, 21, 195-205. [CrossRef] [PubMed]
100. Hopkins, S.; Scorneaux, B.; Huang, Z.; Murray, M.G.; Wring, S.; Smitley, C.; Harris, R.; Erdmann, F.; Fischer, G.; Ribeill, Y. SCY-635, a novel nonimmunosuppressive analog of cyclosporine that exhibits potent inhibition of hepatitis C virus RNA replication in vitro. Antimicrob. Agents Chemother. 2010, 54, 660-672. [CrossRef] [PubMed]
101. Garbelli, A.; Radi, M.; Falchi, F.; Beermann, S.; Zanoli, S.; Manetti, F.; Dietrich, U.; Botta, M.; Maga, G. Targeting the human DEAD-box polypeptide 3 (DDX3) RNA helicase as a novel strategy to inhibit viral replication. Curr. Med. Chem. 2011, 18, 3015-3027. [CrossRef] [PubMed]
102. Kumar, N.; Liang, Y.; Parslow, T.G.; Liang, Y. Receptor tyrosine kinase inhibitors block multiple steps of influenza a virus replication. J. Virol. 2011, 85, 2818-2827. [CrossRef] [PubMed]
103. Vidalain, P.O.; Lucas-Hourani, M.; Helynck, O.; Tangy, F.; Munier-Lehmann, H. Stimulation of the antiviral innate immune response by pyrimidine biosynthesis inhibitors: A surprise of phenotypic screening. Med. Sci. 2015, 31, 98-104.
104. Pawlotsky, J.M. What are the pros and cons of the use of host-targeted agents against hepatitis C? Antivir. Res. 2014, 105, 22-25. [CrossRef] [PubMed]
105. Chatterji, U.; Lim, P.; Bobardt, M.D.; Wieland, S.; Cordek, D.G.; Vuagniaux, G.; Chisari, F.; Cameron, C.E.; Targett-Adams, P.; Parkinson, T.; et al. HCV resistance to cyclosporin A does not correlate with a resistance of the NS5A-cyclophilin A interaction to cyclophilin inhibitors. J. Hepatol. 2010, 53, 50-56. [CrossRef] [PubMed]
106. Delang, L.; Vliegen, I.; Froeyen, M.; Neyts, J. Comparative Study of the Genetic Barriers and Pathways towards Resistance of Selective Inhibitors of Hepatitis C Virus Replication. Antimicrob. Agents Chemother. 2011, 55, 4103-4113. [CrossRef] [PubMed]
107. Sheldon, J.; Beach, N.M.; Moreno, E.; Gallego, I.; Pineiro, D.; Martinez-Salas, E.; Gregori, J.; Quer, J.; Esteban, J.I.; Rice, C.M.; et al. Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus. J. Virol. 2014, 88, 12098-12111. [CrossRef] [PubMed]
108. Sullivan, J.C.; de Meyer, S.; Bartels, D.J.; Dierynck, I.; Zhang, E.Z.; Spanks, J.; Tigges, A.M.; Ghys, A.; Dorrian, J.; Adda, N.; et al. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin. Infect. Dis. 2013, 57, 221-229. [CrossRef] [PubMed]
109. Sato, M.; Maekawa, S.; Komatsu, N.; Tatsumi, A.; Miura, M.; Muraoka, M.; Suzuki, Y.; Amemiya, F.; Takano, S.; Fukasawa, M.; et al. Deep sequencing and phylogenetic analysis of variants resistant to interferon-based protease inhibitor therapy in chronic hepatitis induced by genotype 1b hepatitis C virus. J. Virol. 2015, 89, 6105-6116. [CrossRef] [PubMed]
110. Paolucci, S.; Fiorina, L.; Mariani, B.; Gulminetti, R.; Novati, S.; Barbarini, G.; Bruno, R.; Baldanti, F. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol. J. 2013, 10. [CrossRef] [PubMed]
111. Suzuki, F.; Sezaki, H.; Akuta, N.; Suzuki, Y.; Seko, Y.; Kawamura, Y.; Hosaka, T.; Kobayashi, M.; Saito, S.; Arase, Y.; et al. Prevalence of hepatitis C virus variants resistant to NS3 protease inhibitors or the NS5A inhibitor (BMS-790052) in hepatitis patients with genotype 1b. J. Clin. Virol. 2012, 54, 352-354. [CrossRef] [PubMed]
112. Margeridon-Thermet, S.; le Pogam, S.; Li, L.; Liu, T.F.; Shulman, N.; Shafer, R.W.; Najera, I. Similar prevalence of low-abundance drug-resistant variants in treatment-naive patients with genotype 1a and 1b hepatitis C virus infections as determined by ultradeep pyrosequencing. PLoS ONE 2014, 9, e105569. [CrossRef] [PubMed]
113. Hernandez, D.; Zhou, N.; Ueland, J.; Monikowski, A.; McPhee, F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J. Clin. Virol. 2013, 57, 13-18. [CrossRef] [PubMed]
114. Alves, R.; Queiroz, A.T.; Pessoa, M.G.; da Silva, E.F.; Mazo, D.F.; Carrilho, F.J.; Carvalho-Filho, R.J.; de Carvalho, I.M. The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank. J. Viral Hepat. 2013, 20, 414-421. [CrossRef] [PubMed]
115. Trimoulet, P.; Pinson, P.; Papuchon, J.; Foucher, J.; Vergniol, J.; Chermak, F.; Wittkop, L.; Castaing, N.; Merrouche, W.; Reigadas, S.; et al. Dynamic and rapid changes in viral quasispecies by UDPS in chronic hepatitis C patients receiving telaprevir-based therapy. Antivir. Ther. 2013, 18, 723-727. [CrossRef] [PubMed]
116. Ruggiero, T.; Proietti, A.; Boglione, L.; Milia, M.G.; Allice, T.; Burdino, E.; Orofino, G.; Bonora, S.; di Perri, G.; Ghisetti, V. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naive patients with chronic hepatitis: Single-centre experience. Arch. Virol. 2015. in press. [CrossRef] [PubMed]
117. Sarrazin, C.; Lathouwers, E.; Peeters, M.; Daems, B.; Buelens, A.; Witek, J.; Wyckmans, Y.; Fevery, B.; Verbinnen, T.; Ghys, A.; et al. Prevalence of the hepatitis C virus NS3 polymorphism Q80K in genotype 1 patients in the European region. Antivir. Res. 2015, 116, 10-16. [CrossRef] [PubMed]
118. McCloskey, R.M.; Liang, R.H.; Joy, J.B.; Krajden, M.; Montaner, J.S.; Harrigan, P.R.; Poon, A.F. Global origin and transmission of hepatitis C virus nonstructural protein 3 Q80K polymorphism. J. Infect. Dis. 2015, 211, 1288-1295. [CrossRef] [PubMed]
119. Lenz, O.; de Bruijne, J.; Vijgen, L.; Verbinnen, T.; Weegink, C.; van Marck, H.; Vandenbroucke, I.; Peeters, M.; Simmen, K.; Fanning, G.; Verloes, R.; Picchio, G.; Reesink, H. Efficacy of re-treatment with TMC435 as combination therapy in hepatitis C virus-infected patients following TMC435 monotherapy. Gastroenterology 2012, 143, 1176-1178. [CrossRef] [PubMed]
120. Krishnan, P.; Tripathi, R.; Schnell, G.; Reisch, T.; Beyer, J.; Irvin, M.; Xie, W.; Larsen, L.; Cohen, D.; Podsadecki, T.; et al. Resistance Analysis of Baseline and Treatment-Emergent Variants in the AVIATOR Study With Paritaprevir/r, Ombitasvir and Dasabuvir in HCV Genotype 1. Antimicrob. Agents Chemother. 2015, 59, 5445-5454. [CrossRef] [PubMed]
121. Ruiz-Jarabo, C.M.; Arias, A.; Baranowski, E.; Escarmís, C.; Domingo, E. Memory in viral quasispecies. J. Virol. 2000, 74, 3543-3547. [CrossRef] [PubMed]
122. Briones, C.; Domingo, E.; Molina-París, C. Memory in retroviral quasispecies: Experimental evidence and theoretical model for human immunodeficiency virus. J. Mol. Biol. 2003, 331, 213-229. [CrossRef]
123. Briones, C.; Domingo, E. Minority report: Hidden memory genomes in HIV-1 quasispecies and possible clinical implications. AIDS Rev. 2008, 10, 93-109. [PubMed]
124. Howe, A.Y.; Long, J.; Nickle, D.; Barnard, R.; Thompson, S.; Howe, J.; Alves, K.; Wahl, J. Long-term follow-up of patients receiving boceprevir for treatment of chronic hepatitis C. Antivir. Res. 2015, 113, 71-78. [CrossRef] [PubMed]
125. Susser, S.; Vermehren, J.; Forestier, N.; Welker, M.W.; Grigorian, N.; Fuller, C.; Perner, D.; Zeuzem, S.; Sarrazin, C. Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir. J. Clin. Virol. 2011, 52, 321-327. [CrossRef] [PubMed]
126. Yoshimi, S.; Imamura, M.; Murakami, E.; Hiraga, N.; Tsuge, M.; Kawakami, Y.; Aikata, H.; Abe, H.; Hayes, C.N.; Sasaki, T.; et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J. Med. Virol. 2015, 87, 1913-1920. [CrossRef] [PubMed]
127. Ruiz-Jarabo, C.M.; Arias, A.; Molina-París, C.; Briones, C.; Baranowski, E.; Escarmís, C.; Domingo, E. Duration and fitness dependence of quasispecies memory. J. Mol. Biol. 2002, 315, 285-296. [CrossRef] [PubMed]
128. Lohmann, V.; Korner, F.; Koch, J.; Herian, U.; Theilmann, L.; Bartenschlager, R. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285, 110-113. [CrossRef] [PubMed]
129. Lohmann, V.; Bartenschlager, R. On the history of hepatitis C virus cell culture systems. J. Med. Chem. 2014, 57, 1627-1642. [CrossRef] [PubMed]
130. Steinmann, E.; Pietschmann, T. Cell culture systems for hepatitis C virus. Curr. Top. Microbiol. Immunol. 2013, 369, 17-48. [PubMed]
131. Gao, M.; Nettles, R.E.; Belema, M.; Snyder, L.B.; Nguyen, V.N.; Fridell, R.A.; Serrano-Wu, M.H.; Langley, D.R.; Sun, J.H.; O'Boyle, D.R., II; et al. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature 2010, 465, 96-100. [CrossRef] [PubMed]
132. Lindenbach, B.D.; Evans, M.J.; Syder, A.J.; Wolk, B.; Tellinghuisen, T.L.; Liu, C.C.; Maruyama, T.; Hynes, R.O.; Burton, D.R.; McKeating, J.A.; et al. Complete replication of hepatitis C virus in cell culture. Science 2005, 309, 623-626. [CrossRef] [PubMed]
133. Wakita, T.; Pietschmann, T.; Kato, T.; Date, T.; Miyamoto, M.; Zhao, Z.; Murthy, K.; Habermann, A.; Krausslich, H.G.; Mizokami, M.; et al. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11, 791-796. [CrossRef] [PubMed]
134. Zhong, J.; Gastaminza, P.; Cheng, G.; Kapadia, S.; Kato, T.; Burton, D.R.; Wieland, S.F.; Uprichard, S.L.; Wakita, T.; Chisari, F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 2005, 102, 9294-9299. [CrossRef] [PubMed]
135. Scheel, T.K.; Gottwein, J.M.; Jensen, T.B.; Prentoe, J.C.; Hoegh, A.M.; Alter, H.J.; Eugen-Olsen, J.; Bukh, J. Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization. Proc. Natl. Acad. Sci. USA 2008, 105, 997-1002. [CrossRef] [PubMed]
136. Jensen, T.B.; Gottwein, J.M.; Scheel, T.K.; Hoegh, A.M.; Eugen-Olsen, J.; Bukh, J. Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: Failure of homologous neutralizing-antibody treatment to control infection. J. Infect. Dis. 2008, 198, 1756-1765. [CrossRef] [PubMed]
137. Gottwein, J.M.; Scheel, T.K.; Jensen, T.B.; Lademann, J.B.; Prentoe, J.C.; Knudsen, M.L.; Hoegh, A.M.; Bukh, J. Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: Role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology 2009, 49, 364-377. [CrossRef] [PubMed]
138. Pietschmann, T.; Kaul, A.; Koutsoudakis, G.; Shavinskaya, A.; Kallis, S.; Steinmann, E.; Abid, K.; Negro, F.; Dreux, M.; Cosset, F.L.; et al. Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras. Proc. Natl. Acad. Sci. USA 2006, 103, 7408-7413. [CrossRef] [PubMed]
139. Yi, M.; Ma, Y.; Yates, J.; Lemon, S.M. Compensatory mutations in E1, p7, NS2, and NS3 enhance yields of cell culture-infectious intergenotypic chimeric hepatitis C virus. J. Virol. 2007, 81, 629-638. [CrossRef] [PubMed]
140. Gottwein, J.M.; Scheel, T.K.; Hoegh, A.M.; Lademann, J.B.; Eugen-Olsen, J.; Lisby, G.; Bukh, J. Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses. Gastroenterology 2007, 133, 1614-1626. [CrossRef] [PubMed]
141. Scheel, T.K.; Gottwein, J.M.; Carlsen, T.H.; Li, Y.P.; Jensen, T.B.; Spengler, U.; Weis, N.; Bukh, J. Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations. J. Virol. 2011, 85, 2891-2906. [CrossRef] [PubMed]
142. Prentoe, J.; Jensen, T.B.; Meuleman, P.; Serre, S.B.; Scheel, T.K.; Leroux-Roels, G.; Gottwein, J.M.; Bukh, J. Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization. J. Virol. 2011, 85, 2224-2234. [CrossRef] [PubMed]
143. Griffin, S.; Stgelais, C.; Owsianka, A.M.; Patel, A.H.; Rowlands, D.; Harris, M. Genotype-dependent sensitivity of hepatitis C virus to inhibitors of the p7 ion channel. Hepatology 2008, 48, 1779-1790. [CrossRef] [PubMed]
144. Gottwein, J.M.; Scheel, T.K.; Jensen, T.B.; Ghanem, L.; Bukh, J. Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses. Gastroenterology 2011, 141, 1067-1079. [CrossRef] [PubMed]
145. Scheel, T.K.; Gottwein, J.M.; Mikkelsen, L.S.; Jensen, T.B.; Bukh, J. Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α. Gastroenterology 2011, 140, 1032-1042. [CrossRef] [PubMed]
146. Scheel, T.K.; Prentoe, J.; Carlsen, T.H.; Mikkelsen, L.S.; Gottwein, J.M.; Bukh, J. Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems. PLoS Pathog. 2012, 8, e1002696. [CrossRef] [PubMed]
147. Galli, A.; Scheel, T.K.; Prentoe, J.C.; Mikkelsen, L.S.; Gottwein, J.M.; Bukh, J. Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing core-NS2 and NS5A of genotypes 1-7. J. Gen. Virol. 2013, 94, 2221-2235. [CrossRef] [PubMed]
148. Gottwein, J.M.; Jensen, S.B.; Li, Y.P.; Ghanem, L.; Scheel, T.K.; Serre, S.B.; Mikkelsen, L.; Bukh, J. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. Antimicrob. Agents Chemother. 2013, 57, 1291-1303. [CrossRef] [PubMed]
149. Gottwein, J.M.; Jensen, S.B.; Serre, S.B.; Ghanem, L.; Scheel, T.K.; Jensen, T.B.; Krarup, H.; Uzcategui, N.; Mikkelsen, L.S.; Bukh, J. Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor. Antimicrob. Agents Chemother. 2013, 57, 6034-6049. [CrossRef] [PubMed]
150. Li, Y.P.; Ramirez, S.; Humes, D.; Jensen, S.B.; Gottwein, J.M.; Bukh, J. Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors. Gastroenterology 2014, 146, 812-821. [CrossRef] [PubMed]
151. Saeed, M.; Andreo, U.; Chung, H.Y.; Espiritu, C.; Branch, A.D.; Silva, J.M.; Rice, C.M. SEC14L2 enables pan-genotype HCV replication in cell culture. Nature 2015, 524, 471-475. [CrossRef] [PubMed]
152. Yi, M.; Villanueva, R.A.; Thomas, D.L.; Wakita, T.; Lemon, S.M. Production of infectious genotype 1a hepatitis C virus (Hutchinson strain) in cultured human hepatoma cells. Proc. Natl. Acad. Sci. USA 2006, 103, 2310-2315. [CrossRef] [PubMed]
153. Li, Y.P.; Ramirez, S.; Jensen, S.B.; Purcell, R.H.; Gottwein, J.M.; Bukh, J. Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system. Proc. Natl. Acad. Sci. USA 2012, 109, 19757-19762. [CrossRef] [PubMed]
154. Li, Y.P.; Ramirez, S.; Mikkelsen, L.; Bukh, J. Efficient Infectious Cell Culture Systems of the Hepatitis C Virus (HCV) Prototype Strains HCV-1 and H77. J. Virol. 2015, 89, 811-823. [CrossRef] [PubMed]
155. Shimakami, T.; Welsch, C.; Yamane, D.; McGivern, D.; Yi, M.; Zeuzem, S.; Lemon, S.M. Protease Inhibitor-Resistant Hepatitis C Virus Mutants with Reduced Fitness from Impaired Production of Infectious Virus. Gastroenterology 2011, 140, 667-675. [CrossRef] [PubMed]
156. Pietschmann, T.; Zayas, M.; Meuleman, P.; Long, G.; Appel, N.; Koutsoudakis, G.; Kallis, S.; Leroux-Roels, G.; Lohmann, V.; Bartenschlager, R. Production of infectious genotype 1b virus particles in cell culture and impairment by replication enhancing mutations. PLoS Pathog. 2009, 5, e1000475. [CrossRef] [PubMed]
157. Date, T.; Morikawa, K.; Tanaka, Y.; Tanaka-Kaneko, K.; Sata, T.; Mizokami, M.; Wakita, T. Replication and infectivity of a novel genotype 1b hepatitis C virus clone. Microbiol. Immunol. 2012, 56, 308-317. [CrossRef] [PubMed]
158. Buti, M.; Riveiro-Barciela, M.; Esteban, R. Management of Direct Antiviral Agent Failures. J. Hepatol. 2015. [CrossRef] [PubMed]
159. Perales, C.; Iranzo, J.; Manrubia, S.C.; Domingo, E. The impact of quasispecies dynamics on the use of therapeutics. Trends Microbiol. 2012, 20, 595-603. [CrossRef] [PubMed]